Search
Kalaris Therapeutics Inc
KLRSAdd to Watchlist
4.750USD
+0.220+4.86%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
109.21MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of Kalaris Therapeutics Inc is 8.75, ranking 63 out of 387 in the Biotechnology & Medical Research industry. The average price target is 20.00, with a high of 23.00 and a low of 5.00.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
17.857
Target Price
+323.66%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Kalaris Therapeutics Inc
KLRS
9
Beigene Ltd
ONC
27
Ionis Pharmaceuticals Inc
IONS
27
CRISPR Therapeutics AG
CRSP
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Kalaris Therapeutics Inc's price target?
Analysts forecast that Kalaris Therapeutics Inc's price target is USD 20.00, with the highest forecast at USD 23.00 and the lowest forecast at USD 5.00.
How have Kalaris Therapeutics IncKLRS's recent earnings per share performed?
The market expectation was USD -0.46, while Kalaris Therapeutics IncKLRS's earnings per share (EPS) for the previous quarter was USD -0.51. EPS for the next quarter is expected at USD -0.49.
What is the analyst rating for Kalaris Therapeutics Inc?
Based on the ratings of Kalaris Therapeutics Inc's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.